Home › Funds › DAFNA Capital Management LLC › LKFT
DAFNA Capital Management LLC position in LKFT
LAKEFRONT BIOTHERAPEUTICS NV
DAFNA Capital Management LLC reported holding 130,175 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q2 2026 13F filing — a position valued at US$3.9M, representing 0.74% of its reported portfolio and ranking #31 among its reported holdings. DAFNA Capital Management LLC has disclosed LKFT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DAFNA Capital Management LLC's LKFT position evolved
DAFNA Capital Management LLC first disclosed a stake in LKFT in Q3 2023 at 60,175 shares (US$2.1M). The position peaked in Q4 2023 at 130,175 shares, worth US$5.3M. Across 12 filings, DAFNA Capital Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 130,175 shares valued at US$3.9M. Notable position changes include a 116% increase in Q4 2023 (shares fell 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 60.17K | $2.08M | New |
| Q4 2023 | 130.18K | $5.29M | Add |
| Q1 2024 | 130.18K | $4.19M | Hold |
| Q2 2024 | 130.18K | $3.23M | Hold |
| Q3 2024 | 130.18K | $3.75M | Hold |
| Q4 2024 | 130.18K | $3.58M | Hold |
| Q1 2025 | 130.18K | $3.27M | Hold |
| Q2 2025 | 130.18K | $3.64M | Hold |
| Q3 2025 | 130.18K | $4.51M | Hold |
| Q4 2025 | 130.18K | $4.26M | Hold |
| Q1 2026 | 130.18K | $3.91M | Hold |
| Q2 2026 | 130.18K | $3.90M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LKFT and 13F data
LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 17 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$500.2M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LKFT
- GILEAD SCIENCES, INC. 16.71M sh · $500.16M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 3.79M sh · $113.50M · Q2 2026
- Madison Avenue Partners, LP 3.45M sh · $103.37M · Q2 2026
- Prosight Management, LP 2.04M sh · $61.26M · Q2 2026
- EcoR1 Capital, LLC 1.67M sh · $49.98M · Q2 2026
- DME Capital Management, LP 482.75K sh · $14.47M · Q2 2026
More on DAFNA Capital Management LLC
FAQ
How long has DAFNA Capital Management LLC held LKFT?
DAFNA Capital Management LLC has disclosed LKFT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is DAFNA Capital Management LLC's current position in LKFT?
As of Q2 2026, DAFNA Capital Management LLC holds 130.18K shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $3.90M, representing 0.74% of its reported portfolio and ranking #31.
Has DAFNA Capital Management LLC been buying or selling LKFT?
In the latest 13F filing (Q2 2026), DAFNA Capital Management LLC held unchanged its position in LKFT. The position peaked in Q4 2023 at 130.18K shares.
Which other funds hold LKFT?
Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, among 17 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.